Back to News
Market Impact: 0.42
Sanofi, Regeneron Expand Immunology Alliance In Deal Worth Up To $8 Bln
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationProduct Launches
Sanofi and Regeneron expanded their global collaboration to develop and commercialize four next-generation, long-acting immunology antibodies targeting type 2 inflammation. The partnership broadens both companies' immunology pipelines and could support longer-term growth in inflammatory-disease therapies, although no financial terms or development timelines were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
REGN0.72
SNY0.68
More News
- Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership
- Jefferies raises Regeneron stock price target to $930 on partnership
- Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
- Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
- Why the media’s whisper campaign about a Goldman Sachs change at the top is misleading gossip, at best
- Nvidia Faces Questions Over China AI Chip Smuggling Cases